One Year of Netarsudil and Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure : Phase 3, Randomized MERCURY-1 Study
Copyright © 2020 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved..
PURPOSE: A phase 3 trial (MERCURY-1) investigated efficacy and safety of a once-daily, fixed-dose combination (FDC) of netarsudil and latanoprost, compared with each active component, in reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). A planned 3-month analysis demonstrated the superiority of netarsudil/latanoprost FDC over its individual active components at every assessment. Herein, the 12-month efficacy and safety of netarsudil/latanoprost FDC are reported.
DESIGN: Double-masked, randomized, active-controlled, parallel-group trial.
PARTICIPANTS: Patients had unmedicated IOP >20 to <36 mmHg in both eyes at 8:00 am and met other standard criteria for OAG or OHT.
METHODS: Randomization to once-daily netarsudil 0.02%/latanoprost 0.005% FDC (n = 238), netarsudil 0.02% only (n = 243), or latanoprost 0.005% only (n = 237). Patients instilled study drug into each eye between 8:00 pm and 10:00 pm.
MAIN OUTCOME MEASURES: IOP was obtained at 8:00 am, 10:00 am, and 4:00 pm on day 1 (baseline); at weeks 2 and 6; and at months 3, 6, 9, and 12. Ocular and systemic safety were evaluated up to month 12.
RESULTS: Netarsudil/latanoprost FDC maintained statistically superior IOP lowering compared to its components at every assessment for 12 months. Least squares mean diurnal IOP (± standard error) at month 12 was 16.2 ± 0.23 mmHg for netarsudil/latanoprost FDC, 17.9 ± 0.20 mmHg for netarsudil, and 17.6 ± 0.18 mmHg for latanoprost (P < 0.05 for netarsudil/latanoprost FDC versus each comparator). The safety profile of netarsudil/latanoprost FDC was consistent with its individual components. The proportion of patients who experienced at least 1 adverse event (AE) was 82.8% (197/238) in the netarsudil/latanoprost FDC group, 78.2% (190/243) in the netarsudil group, and 54.0% (128/237) in the latanoprost group. The most common AE was conjunctival hyperemia, mostly of mild severity, with an incidence of 63.0% in the netarsudil/latanoprost FDC treatment group compared with 51.4% in the netarsudil group and 21.9% in the latanoprost group.
CONCLUSIONS: Results at 12 months revealed superior efficacy for netarsudil/latanoprost FDC compared with the individual components, netarsudil and latanoprost, at every time point assessed and an ocular tolerability profile similar to that of netarsudil alone.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
---|---|
Enthalten in: |
Ophthalmology. Glaucoma - 3(2020), 5 vom: 22. Sept., Seite 327-338 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Brubaker, Jacob W [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 14.09.2021 Date Revised 14.09.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.ogla.2020.05.008 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM313434018 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM313434018 | ||
003 | DE-627 | ||
005 | 20231225150549.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ogla.2020.05.008 |2 doi | |
028 | 5 | 2 | |a pubmed24n1044.xml |
035 | |a (DE-627)NLM313434018 | ||
035 | |a (NLM)32768361 | ||
035 | |a (PII)S2589-4196(20)30157-5 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Brubaker, Jacob W |e verfasserin |4 aut | |
245 | 1 | 0 | |a One Year of Netarsudil and Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure |b Phase 3, Randomized MERCURY-1 Study |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.09.2021 | ||
500 | |a Date Revised 14.09.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. | ||
520 | |a PURPOSE: A phase 3 trial (MERCURY-1) investigated efficacy and safety of a once-daily, fixed-dose combination (FDC) of netarsudil and latanoprost, compared with each active component, in reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). A planned 3-month analysis demonstrated the superiority of netarsudil/latanoprost FDC over its individual active components at every assessment. Herein, the 12-month efficacy and safety of netarsudil/latanoprost FDC are reported | ||
520 | |a DESIGN: Double-masked, randomized, active-controlled, parallel-group trial | ||
520 | |a PARTICIPANTS: Patients had unmedicated IOP >20 to <36 mmHg in both eyes at 8:00 am and met other standard criteria for OAG or OHT | ||
520 | |a METHODS: Randomization to once-daily netarsudil 0.02%/latanoprost 0.005% FDC (n = 238), netarsudil 0.02% only (n = 243), or latanoprost 0.005% only (n = 237). Patients instilled study drug into each eye between 8:00 pm and 10:00 pm | ||
520 | |a MAIN OUTCOME MEASURES: IOP was obtained at 8:00 am, 10:00 am, and 4:00 pm on day 1 (baseline); at weeks 2 and 6; and at months 3, 6, 9, and 12. Ocular and systemic safety were evaluated up to month 12 | ||
520 | |a RESULTS: Netarsudil/latanoprost FDC maintained statistically superior IOP lowering compared to its components at every assessment for 12 months. Least squares mean diurnal IOP (± standard error) at month 12 was 16.2 ± 0.23 mmHg for netarsudil/latanoprost FDC, 17.9 ± 0.20 mmHg for netarsudil, and 17.6 ± 0.18 mmHg for latanoprost (P < 0.05 for netarsudil/latanoprost FDC versus each comparator). The safety profile of netarsudil/latanoprost FDC was consistent with its individual components. The proportion of patients who experienced at least 1 adverse event (AE) was 82.8% (197/238) in the netarsudil/latanoprost FDC group, 78.2% (190/243) in the netarsudil group, and 54.0% (128/237) in the latanoprost group. The most common AE was conjunctival hyperemia, mostly of mild severity, with an incidence of 63.0% in the netarsudil/latanoprost FDC treatment group compared with 51.4% in the netarsudil group and 21.9% in the latanoprost group | ||
520 | |a CONCLUSIONS: Results at 12 months revealed superior efficacy for netarsudil/latanoprost FDC compared with the individual components, netarsudil and latanoprost, at every time point assessed and an ocular tolerability profile similar to that of netarsudil alone | ||
650 | 4 | |a Clinical Trial, Phase III | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Benzoates |2 NLM | |
650 | 7 | |a Ophthalmic Solutions |2 NLM | |
650 | 7 | |a beta-Alanine |2 NLM | |
650 | 7 | |a 11P2JDE17B |2 NLM | |
650 | 7 | |a Latanoprost |2 NLM | |
650 | 7 | |a 6Z5B6HVF6O |2 NLM | |
650 | 7 | |a netarsudil |2 NLM | |
650 | 7 | |a W6I5QDT7QI |2 NLM | |
700 | 1 | |a Teymoorian, Savak |e verfasserin |4 aut | |
700 | 1 | |a Lewis, Richard A |e verfasserin |4 aut | |
700 | 1 | |a Usner, Dale |e verfasserin |4 aut | |
700 | 1 | |a McKee, Hayley J |e verfasserin |4 aut | |
700 | 1 | |a Ramirez, Nancy |e verfasserin |4 aut | |
700 | 1 | |a Kopczynski, Casey C |e verfasserin |4 aut | |
700 | 1 | |a Heah, Theresa |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Ophthalmology. Glaucoma |d 2018 |g 3(2020), 5 vom: 22. Sept., Seite 327-338 |w (DE-627)NLM294826912 |x 2589-4196 |7 nnns |
773 | 1 | 8 | |g volume:3 |g year:2020 |g number:5 |g day:22 |g month:09 |g pages:327-338 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ogla.2020.05.008 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 3 |j 2020 |e 5 |b 22 |c 09 |h 327-338 |